Breast cancer 2013 - Interpretation of new and known data;Mammakarzinom 2013 Interpretation neuer und bekannter Daten

Geburtshilfe und Frauenheilkunde

Volumn 73, Issue 6, 2013, Pages 584-598

  Lux, M P ^a   Maass, N ^b   Schutz F ^c   Schwidde, I ^d   Fasching, P A ^a   Fehm, T ^e   Janni, W ^f   Kummel S ^d   Kolberg, H C ^g   Luftner D ^h  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g Marien Hospital Bottrop gGmbH   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

breast cancer; local recurrence; metastases; treatment; trials

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; HEALTH ECONOMICS; HUMAN; PHARMACOGENOMICS; PROGNOSIS; REVIEW;

EID: 84879482895     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1328691     Document Type: Review

References (76)

1. Fasching P. A., Ekici A. B., Adamietz B. R. et al. Breast cancer risk - genes, environment and clinics. Geburtsh Frauenheilk: 2011; 71 1056 1066
2. Rauh C., Hack C. C., Haberle L. et al. Percent mammographic density and dense area as risk factors for breast cancer. Geburtsh Frauenheilk: 2012; 72 727 733
3. Vachon C. M., Scott C. G., Fasching P. A. et al. Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev: 2012; 21 1156 1166
4. Heusinger K., Loehberg C. R., Haeberle L. et al. Mammographic density as a risk factor for breast cancer in a German case-control study. Eur J Cancer Prev: 2011; 20 1 8
5. Garcia-Closas M., Couch F. J., Lindstrom S. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet: 2013; 45 392 398
6. Bojesen S. E., Pooley K. A., Johnatty S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet: 2013; 45 371 384
7. Michailidou K., Hall P., Gonzalez-Neira A. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet: 2013; 45 353 361
8. Nickels S., Truong T., Hein R. et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genetics: 2013; 9 e1003284
9. Gaudet M. M., Kuchenbaecker K. B., Vijai J. et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genetics: 2013; 9 e1003173
10. French J. D., Ghoussaini M., Edwards S. L. et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet: 2013; 10.1016/j.ajhg.2013.01.002
11. Antoniou A. C., Wang X., Fredericksen Z. S. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet: 2010; 42 885 892
12. Antoni S., Sasco A. J., Dos Santos Silva I. et al. Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis. Breast Cancer Res Treat: 2013; 137 337 347
13. Heusinger K., Jud S. M., Haberle L. et al. Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Res Treat: 2012; 135 885 892
14. Heusinger K., Jud S. M., Haberle L. et al. Association of mammographic density with hormone receptors in invasive breast cancers - results from a case-only study. Int J Cancer: 2012; 10.1002/ijc.27515
15. Fasching P. A., Pharoah P. D., Cox A. et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet: 2012; 21 3926 3939
16. Fisher B., Anderson S., Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med: 2002; 347 1233 1241 (Pubitemid 35176242)
17. Veronesi U., Cascinelli N., Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med: 2002; 347 1227 1232 (Pubitemid 35176241)
18. Giuliano A. E. Lymphatic mapping and sentinel node biopsy in breast cancer. JAMA: 1997; 277 791 792 (Pubitemid 27111311)
19. Bani H. A., Fasching P. A., Lux M. M. et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. Patient Educ Couns: 2007; 66 311 318 (Pubitemid 46726949)
20. Haviland J. S., Agrawal R., Aird E. et al. The UK START (Standardisation of Breast Radiotherapy) Trials: 10-year follow-up results. Cancer Res: 2012; 72 24 100s
21. Flyger H., Massarut S., Alvarado M. et al. Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial- updated analysis of local recurrence and first analysis of survival. Cancer Res: 2012; 72 24 100s
22. Boughey J. C., Suman V. J., Mittendorf E. A. et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy - results from the ACOSOG Z1071 trial. Cancer Res: 2012; 72 24 94s
23. Kuehn T., Bauerfeind I. GP, Fehm T. et al. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res: 2012; 72 24 95s
24. von Minckwitz G., Untch M., Blohmer J. U. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol: 2012; 10.1200/JCO.2011.38.8595
25. Denkert C., Huober J., Loibl S. et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res: 2013; 15 R11
26. Witzel I., Loibl S., von Minckwitz G. et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer: 2012; 107 956 960
27. Fasching P. A., Heusinger K., Haeberle L. et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer: 2011; 11 486
28. Untch M., Fasching P. A., Konecny G. E. et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol: 2011; 29 3351 3357
29. Untch M., Fasching P. A., Konecny G. E. et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol: 2011; 22 1988 1998
30. Untch M., Loibl S., Bischoff J. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol: 2012; 13 135 144
31. Untch M., Rezai M., Loibl S. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol: 2010; 28 2024 2031
32. Untch M., von Minckwitz G., Konecny G. E. et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol: 2011; 22 1999 2006
33. von Minckwitz G., Eidtmann H., Loibl S. et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol: 2011; 22 301 306
34. von Minckwitz G., Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med: 2012; 366 299 309
35. von Minckwitz G., Jonat W., Fasching P. et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat: 2005; 89 165 172 (Pubitemid 40249050)
36. von Minckwitz G., Rezai M., Loibl S. et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol: 2010; 28 2015 2023
37. von Minckwitz G., Untch M., Nuesch E. et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat: 2011; 125 145 156
38. Fasching P. A., Jud S. M., Hauschild M. et al. Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results. Cancer Res: 2012; 72 24 123s
39. Cortazar P., Zhang L., Untch M. et al. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res: 2012; 72 24 93s
40. Anders C. K., Hsu D. S., Broadwater G. et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol: 2008; 26 3324 3330
41. Loibl S., Jackisch C., Gade S. et al. Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res: 2012; 72 24 96s
42. Cameron D., Brown J., Dent R. et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple negative breast cancer. Cancer Res: 2012; 72 24 108s
43. Carmeliet P., Pallaud C., Deurloo R. J. et al. Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple negative early breast cancer (BC). Cancer Res: 2012; 72 24 321s
44. Lambrechts D., Claes B., Delmar P. et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol: 2012; 13 724 733
45. Lambrechts D., Lenz H. J., de Haas S. et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol: 2013; 31 1219 1230
46. Moebus V., Schneeweis A., du Bois A. et al. Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes. Cancer Res: 2012; 72 24 97s
47. Aebi S., Gelber S., Lang I. et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Cancer Res: 2012; 72 24 96s
48. Davies C., Pan H., Godwin J. et al. ATLAS - 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ disease: Effects on outcome in the first and in the second decade after diagnosis. Cancer Res: 2012; 72 24 89s
49. Metzger O., Giobbie-Hurder A., Mallon E. et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. Cancer Res: 2012; 72 24 89s
50. Luftner D., Lux M. P., Maass N. et al. Advances in breast cancer - looking back over the year. Geburtsh Frauenheilk: 2012; 72 1117 1129
51. Pivot X., Romieu G., Bonnefoi H. et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res: 2012; 72 24 104s
52. Earl H. M., Cameron D. A., Miles D. et al. PERSEPHONE: duration of trastuzumab with chemotherapy in women with HER2 positive early breast cancer. Cancer Res: 2012; 72 24 557s
53. Di Leo A., Jerusalem G., Petruzelka L. et al. Final analysis of overall survival for the phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Res: 2012; 72 24 90s
54. Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med: 2012; 366 520 529
55. Piccart M., Baselga J., Noguchi S. et al. Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Cancer Res: 2012; 72 24 492s
56. Finn R. S., Crown J. P., Lang I. et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Res: 2012; 72 24 91s
57. Swain S. M., Kim S. B., Cortes J. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol: 2013; 14 461 471
58. Baselga J., Cortés J., Im S. A. et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res: 2012; 72 24 103s
59. Hartkopf A. D., Banys M., Krawczyk N. et al. Circulating tumor cells in early-stage breast cancer. Geburtsh Frauenheilk: 2011; 71 1067 1072
60. Jaeger B. AS, Rack B. K., Andergassen U. et al. Circulating tumor cells (CTC) may express HER2/neu in patients with early HER2/neu negative breast cancer - results of the German SUCCESS C trial. Cancer Res: 2012; 72 24 215s
61. Sgroi D. C., Sestak I., Zhang Y. et al. Evaluation of prognostic and predictive performance of breast cancer index and its components in hormonal receptor-positive breast cancer patients: a TransATAC study. Cancer Res: 2012; 72 24 248s
62. Dubsky P., Brase J. C., Fisch K. et al. The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients. Cancer Res: 2012; 72 24 101s
63. Cheang M. C., Chia S. K., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst: 2009; 101 736 750
64. Schmidt M., Fasching P. A., Beckmann M. W. et al. Biomarkers in breast cancer - an update. Geburtsh Frauenheilk: 2012; 72 819 832
65. Denkert C., Blohmer J. U., Müller B. M. et al. Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial. Cancer Res: 2012; 72 24 102s
66. Yamauchi H., Nakagawa C., Yamashige S. et al. Societal economics of the 21-gene Recurrence Score® in estrogen receptor-positive early-stage breast cancer in Japan. Cancer Res: 2012; 72 24 458s
67. Blohmer J. U., Rezai M., Kummel S. et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ: 2013; 16 30 40
68. Jacobs V. R., Augustin D., Wischnik A. et al. Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: results of a prospective multi-center study at certified breast cancers in Germany. Cancer Res: 2012; 72 24 455s 456s
69. Conter H. J., Conter D., Wolff R. A. et al. The benefit of targeted therapeutics in medical oncology since the development of trastuzumab. Cancer Res: 2012; 72 24 456s
70. Xie J., Diener M., De G. et al. Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States. Cancer Res: 2012; 72 24 457s
71. Wolff A. C., Hammond M. E., Schwartz J. N. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol: 2007; 25 118 145 (Pubitemid 350003059)
72. Sauter G., Lee J., Bartlett J. M. et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol: 2009; 27 1323 1333
73. Arbeitsgemeinschaft für Gynäkologische Onkologie e.V. Kommission Mamma Diagnostik und Therapie von Patientinnen mit primärem metastasiertem Brustkrebs. Version 2013.10. http://www.ago-online.de
74. Martin M., Loibl S., von Minckwitz G. et al. on behalf of GEICAM (Spanish Breast Cancer Research Group); GBG (German Breast Group) Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - first efficacy results from the LEA study. Cancer Res: 2012; 72 24 91s 92s
75. Kaufman P. A., Awada A., Twelves C. et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res: 2012; 72 24 109s
76. Kreienberg R., Albert U-S, Follmann M. et al. Interdisciplinary GoR level III guidelines for the diagnosis, therapy and follow-up care of breast cancer - Short version - AWMF Registry No.: 032-045OL. Geburtsh Frauenheilk: 2013; 73 556 583